ASCO 2020：11项中国研究成果入选口头报告，17项Poster报告

受亚太地区最初冠疫情因素，原定于5月29日~6月2日在洛杉矶举行的美国政府流行病学学会（ASCO）年会今年将首次以线上形式举办，这是现有最大规模的线上嘉年华。直到现在，内阁会议的简介题目公布，共103个sessions，中都国共有11项研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或拉帕替尼加卡培他松用于HER2+转移性乳腺乳癌（PHOEBE）：一项III期随机测试。

演奏会：转移性乳腺乳癌

写作者：中都国医学科学院养从前院徐兵河名誉教授、马飞名誉教授，复旦大学另有养从前院胡夕春名誉教授等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可切除术三阳性乳腺乳癌规格疗法后卡培他松延续节拍低剂量的III期测试（SYSUCC-001）。

演奏会：乳腺乳癌—发散/地带/常规疗法

写作者：中都山大学防治中都心王树森名誉教授等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

来进行转移性脑的表型特征来预测脑脊液中都可逆DNA检测的概率: 最初工具威慑从前取胜

演奏会：最初工具解决从前问题

写作者：李美芹 李德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对奈及利亚拉非尼作为后半期肠巨噬细胞乳癌的二线疗法：一项免费附加、随机、多中都心II/III期测试。

演奏会：大肠肠道乳癌—大肠冠状动脉、胰腺和实乃

写作者：东南大学亚东养从前院毕锋名誉教授、中都国从前百姓解放军八一养从前院秦叔逵名誉教授等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都国后半期肠乳癌患儿阿帕替尼双线疗法：一项随机、双盲相符合、双盲III期研究

演奏会：大肠肠道乳癌—大肠冠状动脉、胰腺和实乃

写作者：中都国从前百姓解放军八一养从前院秦叔逵名誉教授、东南大学亚东养从前院李秋名誉教授等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期住院性卵巢乳癌二次巨噬细胞减灭术的一项随机III期测试：SOC1 / SGOG-OV2。

时事：儿科乳结核病

写作者：复旦大学另有中都山养从前院臧荣余名誉教授等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性阴囊切除术后常规疗法中都的序贯放低剂量对比基本上PET或实时放低剂量（STARS研究）：一项随机、相符合、免费附加的III期测试。

内阁会议：儿科乳结核病

写作者：中都山大学防治中都心凌云名誉教授、刘继红名誉教授等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比低剂量用于可切除的EGFR基因的N1-N2期NSCLC-随机III期动物模型的最终总体共存统计分析。

时事：肺乳癌—非小巨噬细胞发散-地带/小巨噬细胞/其他胸部

写作者：广东省从前百姓养从前院吴一龙名誉教授等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因寡转移非小巨噬细胞肺乳癌患儿二线嘧啶激酶类固醇联合行动或不联合行动积极前线发散PET：III期免费附加流行病学随机测试（SINDAS）的中都期结果（NCT02893332）。

时事：肺乳癌-非小巨噬细胞转移

写作者：泸州从前百姓养从前院曾铭名誉教授等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对更进一步生还-1（PD-1）的人源化IgG4化学合成联合行动阿昔替尼用于转移性口腔肺癌患儿的Ib期研究的总共存期和生物标志物统计分析。

时事：肺癌/皮肤乳癌

写作者：北京大学养从前院郭军、盛锡楠名誉教授等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容性和结果：常用CAR-T巨噬细胞首次人体测试疗法住院/难治性T巨噬细胞急性淋巴巨噬细胞乳癌（r/r T-ALL）的相容性和。内阁会议：开发中都的疗法核心技术-免疫疗法。写作者：王志欣等简介：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利嘌呤在后半期冠状动脉鳞状巨噬细胞乳癌患儿中都的应用：一项随机的免费附加II期测试（ORIENT-2）。内阁会议：大肠肠道乳癌-大肠冠状动脉乳癌、胰腺乳癌和实乃道乳癌写作者：徐建明名誉教授等简介：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T巨噬细胞对髓母巨噬细胞结节的根除性疗法内阁会议：中都枢神经系统写作者：代红久、孙斌、杨东、徐晖、李晶晶、魏佳、赵旭东简介：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷患儿中都的应用内阁会议：开发中都的疗法学-免疫疗法写作者：沈琳名誉教授等简介：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗法住院/难治性ACUTE淋巴巨噬细胞乳癌/淋巴结节的首例人体动物模型内阁会议: 开发性疗法学-免疫疗法写作者简介：张明志，杨林等简介：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度甲基（T）联合行动应用于后半期单一结节患儿的Ib期研究内阁会议：发展性疗法学便是分子核酸药物和分子生物学写作者：龚继芳，沈琳名誉教授等简介：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动吲哚和nedaplatin疗法住院性或转移性冠状动脉鳞状巨噬细胞乳癌（ESCC）患儿的II期研究。内阁会议：大肠肠道乳癌-大肠冠状动脉、胰腺和实乃道乳癌的研究写作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼简介：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：大肠肠道乳癌-大肠冠状动脉乳癌、胰腺乳癌和实乃管乳癌的双线疗法写作者：宋艳等简介：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种排泄物外体环RNA特征向量用于初始活检时检测高等级乳癌的排泄物外体环RNA特征向量：一项多中都心的回顾性研究内阁会议：泌尿生殖系统乳结核病便是-乳癌、睾丸乳癌和乳癌写作者简介：Liaoyuan Li等简介：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散后半期宫颈乳癌并发低剂量后的常规低剂量内阁会议: 儿科乳结核病写作者简介： 李珉珉等简介：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法肾脏髓性乳癌的连续性：基于ALTER01031测试的统计分析。会衹：外周写作者：上海市养从前院高明名誉教授简介：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗法后患儿结局的因素: ALTER01031的亚组统计分析内阁会议：外周写作者：上海市养从前院高明名誉教授简介：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析预测I-IIIA期非小巨噬细胞肺乳癌（NSCLC）患儿术后住院: GASTO1035和GASTO1018的结果内阁会议：肺乳癌-非小巨噬细胞发散-地带性/小巨噬细胞/小巨噬细胞/其他胸科乳结核病写作者：Si-Yu Wang等简介：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺乳癌（NSCLC）中都EGFR嘧啶激酶类固醇的最初型细菌性程序内阁会议:肺乳癌-非小巨噬细胞转移性肺乳癌写作者简介：赵昕，金玲玲，满宇，欧秋香，宝珠，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、宝珠、薛武、杨绍、范敏简介：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1测试中都后半期肺癌总共存的替代终点内阁会议：肺癌/皮肤乳癌写作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简介：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法住院或转移性细菌性恶性骨质患儿的II期研究内阁会议： 溃疡写作者：唐丽娜，牛晓辉，陈赓，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简介：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 先期评价安罗替尼在后半期溃疡患儿多线疗法中都的相容性和。内阁会议：溃疡写作者：姚伟涛，陈家强，王永，王志，杜最初辉，田志浩，牛晓颖 姚伟涛、陈家强、王永、王鑫、杜鑫辉、田志超、牛晓英简介：11526贴纸：414